Skip to main content
This website uses cookies to ensure you get the best experience. By continuing to use this site, you agree to the use of cookies.

Please note: Your browser does not support the features used on Addgene's website. You may not be able to create an account or request plasmids through this website until you upgrade your browser. Learn more

Please note: Your browser does not fully support some of the features used on Addgene's website. If you run into any problems registering, depositing, or ordering please contact us at [email protected]. Learn more

Addgene

pMP71-HLA-A0201-His Citations (3)

Originally described in: Breadth and Dynamics of HLA-A2- and HLA-B7-Restricted CD8(+) T Cell Responses against Nonstructural Viral Proteins in Acute Human Tick-Borne Encephalitis Virus Infection.
Lampen MH, Uchtenhagen H, Blom K, Varnaite R, Pakalniene J, Dailidyte L, Walchli S, Lindquist L, Mickiene A, Michaelsson J, Schumacher TN, Ljunggren HG, Sandberg JK, Achour A, Gredmark-Russ S Immunohorizons. 2018 Jul 2;2(6):172-184. doi: 10.4049/immunohorizons.1800029.
PubMed Journal

Articles Citing pMP71-HLA-A0201-His

Articles
Breadth and Dynamics of HLA-A2- and HLA-B7-Restricted CD8(+) T Cell Responses against Nonstructural Viral Proteins in Acute Human Tick-Borne Encephalitis Virus Infection. Lampen MH, Uchtenhagen H, Blom K, Varnaite R, Pakalniene J, Dailidyte L, Walchli S, Lindquist L, Mickiene A, Michaelsson J, Schumacher TN, Ljunggren HG, Sandberg JK, Achour A, Gredmark-Russ S. Immunohorizons. 2018 Jul 2;2(6):172-184. doi: 10.4049/immunohorizons.1800029. PubMed
Targeted T cell receptor gene editing provides predictable T cell product function for immunotherapy. Muller TR, Jarosch S, Hammel M, Leube J, Grassmann S, Bernard B, Effenberger M, Andra I, Chaudhry MZ, Kauferle T, Malo A, Cicin-Sain L, Steinberger P, Feuchtinger T, Protzer U, Schumann K, Neuenhahn M, Schober K, Busch DH. Cell Rep Med. 2021 Aug 17;2(8):100374. doi: 10.1016/j.xcrm.2021.100374. eCollection 2021 Aug 17. PubMed
Adoptive cell transfer therapy with ex vivo primed peripheral lymphocytes in combination with anti-PDL1 therapy effectively inhibits triple-negative breast cancer growth and metastasis. Gammelgaard OL, Terp MG, Kirkin AF, Johansen S, Traynor S, Vever H, Guldberg P, Kodahl AR, Gjerstorff MF, Ditzel HJ. Mol Cancer. 2024 Jan 6;23(1):6. doi: 10.1186/s12943-023-01914-8. PubMed

If you have published an article using this material, please email us at [email protected] to have your article added to this page.